The Improvement in Cardiovascular Risk Markers with Glimepiride in Pre-diabetic non-obese Subjects: Similar to Obese Cohort Treated with Metformin

Background: Over a 5- to 9-year period (mean, 7.20.2), we found that glimepiride was more effective than metformin in delaying the progression from pre-diabetes to type 2 diabetes in non-obese subjects. Metformin was the first-line treatment for newly diagnosed diabetics

Read More